Drug Type Fusion protein |
Synonyms rhFVII-Fc + [1] |
Target |
Mechanism tissue factor inhibitors(Tissue factor inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hemophilia A | Phase 2 | CN | 12 Oct 2023 | |
Hemophilia B | Phase 2 | CN | 12 Oct 2023 | |
Factor VII Deficiency | Phase 1 | CN | 14 Dec 2022 | |
Hemorrhage | Phase 1 | CN | 08 Dec 2022 |
Phase 1 | 27 | (jqjmwubiif) = Single dose of SS109 at all 5 doses was well-tolerated. Two adverse events occurred in 2 patients (7.4%) were possibly related to SS109. htofvfndei (bkkfwrzmbg ) | Positive | 17 Jun 2024 |